Clinical Observation of Dapagliflozin Combined with Metformin in the Treatment of Newly-Diagnosed Diabetes Mellitus Type 2
Objective To investigate the clinical efficacy of dapagliflozin combined with metformin in the treatment of newly-diagnosed diabetes mellitus type 2(T2DM).Methods A total of 110 patients with newly-diagnosed T2DM admitted to the hospital from September 2021 to July 2022 were selected and divided into the control group and the observation group based on different treatment regimens,with 55 cases in each group.The patients in the two groups were treated with Metformin Hydrochloride Tablets orally,on this basis,the patients in the observation group were treated with Dapagliflozin Tablets.Both groups were treated for six months.Results The total effective rate in the observation group was 90.91%,which was significantly higher than 74.55%in the control group(P<0.05).Compared with those in the control group,the fasting blood glucose(FBG),2-hour postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c)and homeostasis model assessment of insulin resistance(HOMA-IR)in the observation group significantly decreased after treatment,the fasting insulin(FINS)level and insulin sensitivity index(ISI)significantly increased;the serum von Willebrand Factor(vWF)and endothelin(ET)levels significantly decreased;the superoxide dismutase(SOD)and glutathione peroxidase(GSH-Px)levels significantly increased,the malondialdehyde(MDA)level significantly decreased;the 36-item Short-Form(SF-36)score significantly increased(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Dapagliflozin combined with metformin can effectively improve the ISI,decrease the vascular endothelial factor and oxidative stress levels of patients with newly-diagnosed T2DM.
国家科技期刊平台
NSTL
万方数据
